Common Endocrine Disorders in Children:

- 1. Approach for diagnosis and management of Type 1 Diabetes
- 2. Congenital adrenal hyperplasia
- 3. Congenital hypothyroidism

Approach to a Newly-Diagnosed Diabetic Patient

Definition of Diabetes mellitus :

 A metabolic disorder characterized by the presence of hyperglycemia due to defective insulin secretion, defective insulin action or both.

Classification:

- Type 1 diabetes :
- Type 2 diabetes:
- Other specific types:
 - specific genetically defined forms of diabetes.
 - diabetes associated with other diseases or drug use.

Diagnosis:

• FPG \geq 126 mg/dL

or

 Random PG ≥ 200 mg/dL + symptoms of diabetes

or

• 2hr PG in a 75-g OGTT \geq 200 mg/dL


Genetics:


- Familial clustering of T1DM:
 - monozygotic twins 30-65%
 - dizygotic twins 6-10%
 - siblings 6%
 - mother 2%
 - father 7%
- Monogenic Type 1 Diabetes Mellitus: Rare ex. IPEX syndrome and APS

Environmental Factors:

- ~ 50% of monozygotic twins are discordant for T1DM.
- Variation in urban and rural areas populated by the same ethnic group.
- Change in incidence with migration.
- Increase in incidence in almost all populations in the last few decades.

Pathogenesis of type 1 diabetes :





Insulin

- Secreted by beta cells of pancreas
- Inhibits glycogenolysis and gluconeogenesis in liver
- Stimulates protein synthesis and lipogenesis
- Inhibits lipolysis and proteinolysis

Absence of Insulin

- ↓ lipogenesis + ↑ lipolysis
- \Downarrow protein synthesis + \Uparrow proteinolysis
- ↑ glycogenolysis + ↑ gluconeogenesis

Counter-regulatory Hormones:						
	↓ insulin secretion	↓insulin action	个Glycog- enolysis	个Glucon- eogenesis	个Lipolysis, ketogenesis	↓ glucose utilization
Epinephrine	+	+	+	+	+	+
Cortisol		+	+	+	+	+
GH		+	+	+	+	+
Glucagon			+	+	+	

Clinical Manifestations:

- Polyuria, polydipsia, polyphagia
- weight loss
- Fatigability
- DKA as first presentation.
- Progression may be accelerated by intercurrent illness or stress.

Diabetic Ketoacidosis

- The end result of the metabolic abnormalities resulting from a severe deficiency of insulin.
- DKA is 100% preventable.
- Occurs due to:
 - Non compliance to insulin therapy or
 - Intercurrent illnesses not managed according to the sick day management guidelines.

DKA – History:

- Polyuria , polydipsia, weight loss
- Abdominal pain
- Vomiting
- Confusion
- Tiredness
- Difficulty breathing

DKA – Clinical signs:

• Kussmaul breathing

Lethargy

• Dehydration

• Signs of infection

Diagnosis of DKA:

Glucose > 200 mg/dL

• pH < 7.3

• Ketonuria or ketonemia

• Serum Bicarbonate < 18 mmol/L

Management of DKA with vascular decompensation:

- ABCs.
- Normal saline 10 mL/kg to expand vascular space.
- Decrease to 5-7 mL/kg/hr with KCl.
- Not to infuse NaHCO3 except in certain circumstances.
- Continuous IV insulin infusion 0.1 units/kg/hr.
- Observation and monitoring.
- If acidosis is improving and BG < 270 mg/dL or falls > 90 mg/dL/hr → change IV to D5/Normal Saline with potassium and decrease insulin infusion rate.

Complications of DKA

- Arrhythmias/cardiac arrest 2° to electrolyte abnormalities or possibly long QTc
- Venous thrombosis 2° hypercoagulable state
- Pulmonary edema/ARDS
- Acute renal failure (ATN)
- Bowel ischemia necrosis, stricture formation

Pathophysiology of DKA-related cerebral edema

- Previous hypothesis assumed that fluid shifts caused by osmotic changes were central to DKArelated cerebral edema
- This assumption has not been well supported by clinical data
- Cerebral edema during DKA may be predominantly vasogenic and may result from activation of cell membrane ion transporters in the brain

Risks factors for CE

- Younger age (<5 years)
- New-onset diabetes
- High initial serum urea
- Low initial partial pressure of arterial CO2
- Rapid administration of hypotonic fluids
- IV bolus of insulin
- Early IV insulin infusion (within first hour of administration of fluids)
- Use of bicarbonate

Strategies to prevent Diabetic Ketoacidosis

- To raise public awareness about symptoms and signs of diabetes.
- Beyond diagnosis:
 - Comprehensive diabetes education programs
 - Mental health intervention
 - Home monitoring of ketones or betahydroxybutyrate

Maturity onset diabetes of the young (MODY):

- A heterogeneous group of disorders that result in β-cell dysfunction.
- It is rare, accounting for just 1%–2% of all diabetes.
- It is often misdiagnosed as type 1 or type 2 diabetes, as it is often difficult to distinguish MODY from these two forms.

GENETIC DEFECTS OF β -CELL FUNCTION Maturity-Onset Diabetes of Youth

- Onset 9-25 yr,
- AD inheritance
- A primary defect in insulin secretion.
- Diagnostic Criteria:
 - Diabetes in at least 3 generations with AD
 - Diagnosis before age 25 yr in at least 1 affected subject.

Wolfram Syndrome:

- Diabetes mellitus, diabetes insipidus, optic atrophy, and deafness (DIDMOAD): most prominent findings.
- Other common manifestations:
 - Neurogenic bladder with hydroureteronephrosis,
 - Neurodegenerative illness (most commonly manifesting as ataxia), psychiatric problems, --
 - Hypogonadism.

Insulin Therapy:

Endogenous Insulin Profile






Figure 1. Normal insulin secretion. In the stimulated phase, serum insulin levels increase from within a few minutes before to 30 minutes after a meal. Return to basal level occurs within 2 hours.

Adapted from Galloway and Chance (5).

Galloway et al Horm Metab Res 1994


Idealized insulin time-action profiles





Nature Reviews | Drug Discovery

Long and Rapid- acting insulin




Insulin Pens :



©2003 Mark Harmel All Rights Reserved

Continuous subcutaneous Insulin Infusion (insulin pump):



Insulin Pump:









Inserting insulin pump:




















.

										Bre	akfast		1		Lu	nch		1			Dir	nner					
12	AM	1 A	M 2	AM 3	AM	4 A	M 5/	AM 6	AM 7	AM 8	AM 9	AM 1	0 AM 11	AM 12	PM 1	PM 2	PM 3	PM 4	PM 51	PM 6	PM 7	PM 8	PM 91	PM 10	PM 11	PM	Daily Totals
Wednesday 02/14/2018 ©												hinnn					C	80 42 6.80	&	₽	æ		210 40 6.80	₩.	₩.	₽	Average (2): 145mg/dL Carbs: 82g Insulin: 16.9U Bolus: 80
Thursday 02/15/2018		<	295 3.50						188 40 (7.90			22 [,] 0.800	16			232 (1.30			178 39 7.50			40 2.50	213	211 (0.500)	245 6 1.20	18 2.20	Average (9): 223mg/dL Carbs: 159g Insulin: 42.7U Bolus: 71
Friday 02/16/2018								192 (1.40				\$00000			166 40 7.50				141 40 7.00			202 0.700	212 (0.400	256 28 5.60			Average (7): 201mg/dL Carbs: 108g Insulin: 35.2U Bolus: 64
Saturday 02/17/2018								218 1.90				14 3(5.5(0				166 40 (7.50			41 5.10		45 5.60				254 2.30	Average (6): 181mg/dL Carbs: 156g Insulin: 40.5U Bolus: 69
Sunday 02/18/2018						224 .70			160 33 (5.80			20 0.400	0 235 4 0 2.20				147 5 (1.30		40 6.60		5 0.600	τ	40 5.00	8	8		Average (5): 193mg/dL Carbs: 126g Insulin: 35.5U Bolus: 67
Monday 02/19/2018				24 2.4					189 39 (7.80)	272 1.10	1	241 26 5.20			201 0.700		*	123 40 6.60			225 1.30				220 40 6.80	Average (9): 210mg/dL Carbs: 145g Insulin: 43.9U Bolus: 73
Tuesday 02/20/2018						¢	287 3.30		40 6.60				294 3.00	~~~~			unnnn	133	120 40 6.60				<mark>42</mark> 5.20				Average (4): 209mg/dL Carbs: 122g Insulin: 37.3U Bolus: 66

Glucose monitoring system



HbA1c:

- A reliable index of long-term glycemic control .
- the fraction of hemoglobin to which glucose has been nonenzymatically attached in the blood stream.
- A HbA1c measurement reflects the average blood glucose concentration from the preceding 2-3 mo.

Hypoglycemia

Symptoms of Low Blood Sugar Include:

- Hunger
- Trembling
- Sweating
- Extreme Mood changes
- Extreme tiredness
- Pale
- Dizziness
- Blurred Vision
- Headaches


Hypoglycemia

 These symptoms will always preceede NEUROGLYCOPENIA except in long standing type 1 diabetes/hypoglycemia unawareness.

 Action : confirm blood sugar is less than 72 mg/dL and TREAT WITH CARBOHYDRATE

Hypoglycemia

 Make sure the family has GLUCAGON and knows how to use it



GlucaGen®

[glucagon (rDNA origin) for injection]

Real and Les ratio, injection.

GlucaGen" should be reconstituted with Statle Water for Reconstitution secondiately before use

Do not store for later ane

Read the endcord insert before use Rx ONLY



MENC \$15,000-00





 On 10/Sep./2019:
 FDA approved the Gvoke HypoPen, an emergency glucagon rescue treatment for severe hypoglycemia.



• In July/2019:

FDA approved the first non-injectable form of glucagon, BAQSIMI. The rescue device from Eli Lilly is a powder form of glucagon administered into the nose, and comes in a single-use dispenser.



Sick Day Management

- Counter-regulatory hormones blunt insulin action and elevate glucose levels.
- Frequent blood glucose and ketone monitoring with adjustment of insulin doses.
- The overall goals are to maintain hydration, control glucose levels, and avoid ketoacidosis.


• DO NOT OMIT INSULIN.

Intercurrent Illness

- Check ketones EARLY
 - Always test when nausea or vomiting
 - Urine ketodiastix
 - Precision Xtra meter:
 Earlier detection, no
 need to collect urine



KETONE-Read at exactly 15 seconds.



ISPAD guidelines for retinopathy and nephropathy screening:

 Annually from age 11 years with after 2 years duration

And

• from 9 years with 5 years duration

Congenital Adrenal Hyperplasia

Salt-Losing Crisis in Infancy:

- Severe hyponatremic dehydration
 - Hyperkalemia
 - Metabolic acidosis

 A life-threatening condition in infancy that requires immediate treatment to prevent death.

Differential diagnosis for salt-losing crisis:

- Congenital adrenal hyp<u>er</u>plasia
- Congenital adrenal hypoplasia
- Isolated aldosterone deficiency,
- Pseudohypoaldosteronism

- It is vital to identify this condition and to manage it appropriately, if not → it can result in death.
- All cases benefit from volume replacement.
- Glucocorticoid /mineralocorticoid replacement will not correct electrolyte abnormalities in all cases.

 Defective conversion of 17hydroxyprogesterone to 11-deoxycortisol accounts for more than 95 percent of cases of congenital adrenal hyperplasia. This conversion is mediated by 21-hydroxylase, deficiency of which is caused by mutations in the CYP21A2 gene.

- The initial goals are treatment of hypotension and dehydration, reversal of electrolyte and glucose abnormalities, and correction of cortisol deficiency.
- An intravenous bolus of 10 to 20 mL/kg of normal saline should be administered.
- An intravenous bolus of 2 to 4 mg/kg of 10 percent dextrose should be considered if there is significant hypoglycemia.
- Hyperkalemia should be corrected with the administration of glucose and insulin if necessary, although it typically improves rapidly as a result of the potent mineralocorticoid action of high-dose hydrocortisone.

- An initial dose of hydrocortisone of 50 to 100 mg/m² should be administered as an IV bolus (typical neonatal dose is 25 mg), followed by hydrocortisone at a dose of 50 to 100 mg/m² IV per day divided every six hours. Stress doses of hydrocortisone should be continued until the patient is stable and feeding normally.
- During treatment with stress doses of hydrocortisone. mineralocorticoid replacement is unnecessary.
- If the diagnosis of classic 21-hydroxylase deficiency is confirmed, infants should receive glucocorticoid and mineralocorticoid therapy and salt supplementation

Congenital Hypothyroidism

- The detection and treatment of neonates with hypothyroidism should be considered a pediatric emergency. If therapy is not begun soon after birth , developmental delay will result within few weeks to few months.
- Neonatal screening is essential because of the difficulty in making a clinical diagnosis early enough.

Epidemiology

- Prevalence of 1:3500 in white infants.
- Differ significantly among different ethnic groups.
- Female : Male ratio is 2 : 1.

Clinical manifestations of congenital hypothyroidism

- Most infants with C.H. are asymptomatic at birth.
- Birth weight and length are normal, but head size may be slightly increased.
- Prolongation of physiological jaundice may be the earliest sign.
- Decrease activity.
- Feeding difficulties.
- Respiratory difficulties.
- Constipation.
- Subnormal temperature .
- Slow pulse .

- If congenital hypothyroidism goes undetected, these manifestations progress. Retardation of physical and mental development becomes greater over the following months and by 3-6 months of age the clinical picture is fully developed.
- Stunted growth. Short extremities.
- The AF and PF are opened widely.
- Coarse features.
- Protrusion of large tongue.
- Dry, scaly skin.
- Coarse, brittle and scanty hair.
- The muscles are usually hypotonic.

Actions of the thyroid hormones

- Increase the oxidative metabolism: -个 oxygen consumption -个BMR -个glucose metabolism -个 fat metabolism.
- Promote growth and development.
- Influence nervous system development and function. Essential for normal myelination and development of CNS.
- Augmentation of cardiac function.
- Important for normal reproductive function.

Causes of congenital hypothyroidism

- A. PERMANENT :
 - A.a. Permanent primary hypothyroidism.
 - \downarrow T₄ , \uparrow TSH .
 - 1. Thyroid dysgenesis: 85% of permanent C.H.
 - ectopy agenesis. hypoplasia. hemiagenesis.
 - 2. Thyroid dyshormogenesis :
 - -Goiter .
 - -TPO M/C.
 - 3. TSH resistance due to TSH receptor mutation: Rare.

A.b. Permanent central : ↓T4 ,↓ TSH or inappropriately NL TSH.

1. Developmental defect : pituitary or hypothalamic disorders. May have midline defects.

2. Inactivating mutations : - TRH receptor.
- TSH β subunit. – Pit. Transcription factors.

B. TRANSIENT :

- 1. severe iodine deficiency.
- 2. acute iodine overload from iodine-containing antiseptic. rare.
- 3. maternal antithyroid drug treatment : clears in 3-4 days after birth.
- 4. transplacental transfer of TSH-receptor blocking antibodies: - ↓T4, ↑TSH.
- 5. Hypothyroximia of prematurity:

 $-\downarrow$ T4, \downarrow T3, NL TSH.

- adaptation to prematurity rather than true central hypothyroidism.

• Treatment

Levothyroxine

THANK YOU